Skip to main content
Premium Trial:

Request an Annual Quote

Crown Bioscience Collaborates with Horizon on X-MAN Cell Lines

NEW YORK (GenomeWeb News) – Crown Bioscience and Horizon Discovery today announced that they will partner on offering new in vivo X-MAN models as a service to Crown's customers.

Horizon's X-MAN cell lines are used for in vivo and in vitro drug discovery model validation. The Cambridge, UK-baed firm already offers more than 450 X-MAN cell lines, as well as more than 50 phenotypic cell-based assays, and its SyntheTx drug/RNAi screening platform.

"The novel in vivo models we are developing based on the X-MAN cell lines offer new opportunities for clients to collaborate with us at an early stage and validate the models based on their needs," Jean-Pierre Wery, president of Santa Clara, Calif.-based Crown Bioscience said in a statement. "This will allow greater insights and better means to evaluate the therapeutic efficacy of compounds and their impact on key physiological functions."

Financial and other terms of the alliance were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more